Journal of Medical Economics · 2019 · 31 citations · 27 references
MedicineOncologyPharmacoeconomicsCancer EpidemiologyEndocrine OncologyEndocrine PharmacotherapyAndrogen Deprivation TherapyAndrogen TherapyHormonal Cancer TherapyHormonal TherapyProstate CancerToxicity Risk AssessmentDiscontinuation RiskEconomic Burden Of DiseaseEconomic Burden Of IllnessHealthcare Resource UtilizationHormone Therapy DiscontinuationNon-metastatic Castration-resistant Prostate CancerPrognostic Factors AnalysisProstate Cancer Epidemiology
AEs increase the economic burden and therapy discontinuation among nmPC patients receiving secondary hormonal therapies subsequent to ADTs. These patients should be carefully evaluated for AEs to reduce therapy discontinuation, HCRU, and direct medical costs.
27
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Philip W. Kantoff, Celestia S. Higano, Neal D. Shore et al. · New England Journal of Medicine · 2010 · 5.5K citations · Full text
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher, Karim Fizazi, Fred Saad et al. · New England Journal of Medicine · 2012 · 4.6K citations · Full text
Medicine, Oncology, Pharmacology +14
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Matthew R. Smith, Fred Saad, Simon Chowdhury et al. · New England Journal of Medicine · 2018 · 1.3K citations · Full text